FeesSafety
Pluang+

Davion Healthcare to acquire profitable US home healthcare firm for $13.5M to expand services.

Company Fundamentals
29 Oct 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Davion Healthcare to acquire profitable US home healthcare firm for $13.5M to expand services.

Davion Healthcare Plc has agreed to acquire Healthcare Stat Homecare Inc., a profitable home healthcare provider in Philadelphia, for $13.5 million. This acquisition marks the first in Davion's planned series to grow its revenue and healthcare operations by combining proprietary health tech with established service businesses. The deal, expected to close by year-end 2026, will allow Davion to expand into home healthcare delivery and explore integrating its non-invasive monitoring technologies in patient care at home. This move aims to diversify Davion's portfolio and strengthen its presence in the healthcare market.

Davion Healthcare PLC's acquisition news comes as a backdrop to a health sector where 95 of 150 US stocks traded on Pluang rose today. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: Butterfly Network Inc. (BFLY) rose 5.63% to USD 8.25 with a typical hold time of 14 days, Tenet Healthcare Corporation (THC) fell 5.10% to USD 254.80 with a typical hold time of 17 days, and Eli Lilly And Co (LLY) increased 4.11% to USD 1,341.75 with Pluang order activity showing 29% sell and 71% buy, and a typical hold time of 94 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App